[Expression of vasodilator-stimulated phosphoprotein relates to prostate cancer metastasis].

OBJECTIVE: To investigate the relationship of the expression of vasodilator-stimulated phosphoprotein (VASP) with the metastasis and prognosis of prostate cancer. METHODS: Prostate cancer PC3 cells were infected with VASP shRNA and control shRNA lentiviruses, respectively. The invasive ability of the PC3 cells was determined by transwell migration assay, the expression of VASP in the prostate cancer tissue from 56 patients was detected by immunohistochemistry, and the survival rate of the patients was analyzed according to the VASP expression levels and follow-up data after radical prostatectomy. RESULTS: VASP shRNA lentivirus significantly inhibited the expression of VASP and decreased the invasive ability of the PC3 cells as compared with the results obtained in the scramble shRNA and blank control groups (P<0.05). The survival analysis of the 56 prostate cancer patients showed that the time of biochemical recurrence was markedly shorter in the VASP positive and strongly positive groups than in the VASP-negative cases (P<0.05), but with no statistically significant difference between the former two groups (P>0.05). CONCLUSIONS: VASP is involved in the regulation of the invasive ability of prostate cancer PC3 cells, and the differences in the VASP expression are related to the prognosis of prostate cancer.

[Clinical significance of C-reactive protein concentration in the expressed prostatic secretion from chronic prostatitis patients].

OBJECTIVES: To discuss the correlation of C-reactive protein (CRP) concentration in the EPS of chronic prostatitis (CP) patients with CP types, WBC count in EPS, lecithin corpuscles (LLZXT) and chronic prostatitis symptom index (CPSI). METHODS: According to the NIH classification standard, 196 cases of CP were diagnosed by the pro and post massage test (PPMT) and EPS routine, of which 68 were chronic bacterial prostatitis (Type II ), 76 inflammatory chronic non-bacterial prostatitis/chronic pelvic pain syndrome (Type III A) and 52 non-inflammatory chronic non-bacterial prostatitis/chronic pain syndrome (Type III B). Another 50 healthy volunteers were enrolled as normal controls. The CRP concentration in the EPS of all the patients was determined by immunoturbidimetry and 196 groups of data were obtained. RESULTS: The average concentration of CRP was significantly higher in the CP group ( [2.945 +/- 1.996] mg/L) than in the control ( [1.101 +/- 0.440] mg/L) (P < 0. 01) , and it decreased progressively from the Type II to Type III A and Type III B group, with statistical difference between Type III B and Type II or Type III A (P < 0. 01 ), but not between Type II and Type III A (P = 0.058). The CRP concentration was correlated negatively with LLZXT (r = -0.33, P < 0.01) and positively with WBC count (r = 0.63, P < 0.01) and the score on the first 6 items of CPSI (r = 0. 28, P < 0. 01). CONCLUSION: The CRP concentration in EPS, with its significant role in the pathogenesis of CP, may serve as a basis for the diagnosis and classification of CP as well as an objective index for assessing the therapeutic effect on the disease.